<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00362219</url>
  </required_header>
  <id_info>
    <org_study_id>RMC-2468.CTIL</org_study_id>
    <nct_id>NCT00362219</nct_id>
  </id_info>
  <brief_title>Topical Morphine for Analgesia in Patients With Skin Grafts</brief_title>
  <official_title>Topical Morphine for Analgesia in Patients With Skin Grafts</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rambam Health Care Campus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rambam Health Care Campus</source>
  <brief_summary>
    <textblock>
      The management of pain endured by patients after skin grafting is complex. Pain is the single
      most distressing symptom but as it is difficult to manage, it is often under-treated. These
      patients may experience pain from two types of wound: the original injury and from
      &quot;skin-donor&quot; sites, areas of healthy skin from which skin is surgically removed and used to
      cover the original injury. As the section of skin which is removed is standardized, the wound
      created at the donor site is uniform and so provides a model of an acute wound.

      Opioids (such as morphine) are the backbone of treating the moderate to severe pain
      experienced by any patient. But due to their potentially severe side effects and that some
      patients do not experience sufficient relief from the treatment, optimal treatment schedules
      are still being sought after.

      Topically applied morphine has provided effective and safe analgesia in several clinical
      models. We, therefore, wish to apply this treatment modality onto skin-graft donor wounds. If
      found to be effective this could be an appealing non-invasive method to treat the pain of
      this type of wound.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Administration of morphine into the knee joint is the best-studied clinical procedure
      documenting the use of topically-applied opioids. When 1-5 mg morphine were injected into the
      knee joint, patients experienced pain relief for up to 24 hours, whereas similar doses given
      systemically (i.e. intravenously) were effective for 2-4 hours. Furthermore, the analgesic
      effect was reversed when the opioid antagonist naloxone was injected into the knee joint.
      Both these findings indicate that the effect is mediated by local opioid receptors in the
      knee joint.

      Peripheral analgesic effects of opioids are not detectable in normal tissue but appear
      minutes to hours after initiation of inflammation. This suggests that opioid receptors are
      already present in the peripheral nerve terminals but under normal conditions they are not
      functional.

      Research on application of opioids to skin wounds is very sparse and has primarily been
      performed in palliative care patients. These reports demonstrate that topical opioid gel
      (morphine or diamorphine) provided rapid and effective relief. In some patients pain subsided
      within 20 minutes after application with a long-lasting (7-8 hours) effect. Fundamental
      aspects regarding topical application of opioids onto skin wounds are still lacking. For
      example, issues such as optimal dose and dose-effect relationships have not been
      investigated. We hope to determine these in this study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2006</start_date>
  <completion_date type="Actual">May 2010</completion_date>
  <primary_completion_date type="Actual">May 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain score in first 24 hours</measure>
    <time_frame>24 hours after application of the medication</time_frame>
    <description>Sum of the differences in pain scores between the skin-donor site vs. original injury site taken over a 24 hour period after application of the medication.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain Score</measure>
    <time_frame>24 hours after surgery</time_frame>
    <description>Pain score at skin-donor site using an abbreviated form of the McGill Pain Questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time course of analgesia for each drug concentration</measure>
    <time_frame>First 24 hours after surgery</time_frame>
    <description>Time course of analgesia for each drug concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side effects</measure>
    <time_frame>First 24 hours after surgery</time_frame>
    <description>Presence and severity of side effects: (a) central (nausea, vomiting, sedation, purities) and (b) local (burning, tingling, wheal, flare)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Supplementary analgesic medications</measure>
    <time_frame>First 24 hours after surgery</time_frame>
    <description>Concurrent, supplementary, &quot;rescue&quot;, analgesic medication (i.v.or oral morphine), given during the first 24 hours post operatively</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analgesic medicine from 2nd post-operative day until dressings are removed.</measure>
    <time_frame>Day 2 post-surgery through 12th post-op day on average</time_frame>
    <description>Analgesic medication (type and dose), given from the second post-operative day until dressings are removed for the first time (= the 12th post-operataive day, on average).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain score collection</measure>
    <time_frame>Twice daily from day 2 post-op until day 8 post-op</time_frame>
    <description>Pain scores at donor and original injury, twice daily, from the second post-operative day until dressings are removed for the first time - up until 8th post-op day</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Wound assessment</measure>
    <time_frame>Average day 12 post-operative</time_frame>
    <description>Assessment of the wound once the dressings are removed</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Skin Transplantation</condition>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Gel with no active ingredient</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Morphine .25 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Gel with 0.25 mg morphine per 100cm2 square of wound</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Morphine - .75 mg.</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Gel with 0.75 mg morphine per 100cm2 square of wound.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Morphine 1.25 mg.</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Gel with 1.25 mg morphine per 100cm2 square of wound.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Gel with no active ingredient.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Morphine - .25 mg</intervention_name>
    <description>gel with 0.25 mg morphine per 100cm2 square of wound.</description>
    <arm_group_label>Morphine .25 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Morphine</intervention_name>
    <description>Gel with 0.75 mg morphine per 100cm2 square of wound.</description>
    <arm_group_label>Morphine - .75 mg.</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Morphine</intervention_name>
    <description>Gel with 1.25 mg morphine per 100cm2 square of wound.</description>
    <arm_group_label>Morphine 1.25 mg.</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients undergoing skin-grafting

          -  American Society of Anesthesiologists (ASA) classification I-II

          -  Written consent

          -  Either sex

          -  Able to self-asses and report their pain level

        Exclusion Criteria:

          -  Alcohol abuse or addiction - current

          -  Opioids and benzodiazepines abuse - life time

          -  Known hypersensitivity to morphine

          -  Major renal or hepatic dysfunction

          -  Pregnancy or lactation

          -  Sleep-apnoea-syndrome

          -  Diabetes

          -  Participation in other clinical studies
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yehuda Ullman, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rambam Health Care Campus</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Plastic Surgery, Rambam Medical Center</name>
      <address>
        <city>Haifa</city>
        <zip>31096</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <reference>
    <citation>Krajnik M, Zylicz Z, Finlay I, Luczak J, van Sorge AA. Potential uses of topical opioids in palliative care--report of 6 cases. Pain. 1999 Mar;80(1-2):121-5.</citation>
    <PMID>10204724</PMID>
  </reference>
  <reference>
    <citation>Stein C, Comisel K, Haimerl E, Yassouridis A, Lehrberger K, Herz A, Peter K. Analgesic effect of intraarticular morphine after arthroscopic knee surgery. N Engl J Med. 1991 Oct 17;325(16):1123-6.</citation>
    <PMID>1653901</PMID>
  </reference>
  <reference>
    <citation>Porzio G, Aielli F, Verna L, Cannita K, Marchetti P, Ficorella C. Topical morphine in the treatment of painful ulcers. J Pain Symptom Manage. 2005 Oct;30(4):304-5.</citation>
    <PMID>16256893</PMID>
  </reference>
  <reference>
    <citation>Ribeiro MD, Joel SP, Zeppetella G. The bioavailability of morphine applied topically to cutaneous ulcers. J Pain Symptom Manage. 2004 May;27(5):434-9.</citation>
    <PMID>15120772</PMID>
  </reference>
  <reference>
    <citation>Stein A, Yassouridis A, Szopko C, Helmke K, Stein C. Intraarticular morphine versus dexamethasone in chronic arthritis. Pain. 1999 Dec;83(3):525-32.</citation>
    <PMID>10568861</PMID>
  </reference>
  <reference>
    <citation>Zeppetella G, Ribeiro MD. Morphine in intrasite gel applied topically to painful ulcers. J Pain Symptom Manage. 2005 Feb;29(2):118-9.</citation>
    <PMID>15733803</PMID>
  </reference>
  <reference>
    <citation>Stein C, Sch√§fer M, Machelska H. Attacking pain at its source: new perspectives on opioids. Nat Med. 2003 Aug;9(8):1003-8. Review.</citation>
    <PMID>12894165</PMID>
  </reference>
  <verification_date>October 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 8, 2006</study_first_submitted>
  <study_first_submitted_qc>August 8, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 9, 2006</study_first_posted>
  <last_update_submitted>October 27, 2011</last_update_submitted>
  <last_update_submitted_qc>October 27, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 28, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rambam Health Care Campus</investigator_affiliation>
    <investigator_full_name>y_ullmann</investigator_full_name>
    <investigator_title>Head, Plastic Surgery Department</investigator_title>
  </responsible_party>
  <keyword>topical</keyword>
  <keyword>morphine</keyword>
  <keyword>pain</keyword>
  <keyword>skin-wound</keyword>
  <keyword>skin-graft</keyword>
  <keyword>peripheral analgesia</keyword>
  <keyword>burn</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Morphine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

